Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy
Authors:
Open Access
- 9 January 2024
- journal article
- research article
- Published by Wiley in Cancer Reports
- Vol. 7 (2) , e1960
Abstract
Background: Immune checkpoint inhibitors have been reported to have excellent therapeutic effects on various malignant tumors. However, immune‐related adverse events can occur, targeting various organs.Case presentation: A 49‐year‐old male with lung carcinoma was started on carboplatin + pemetrexed + nivolumab (every 3 weeks) + ipilimumab (every 6 weeks), and nivolumab/ipilimumab was administered in the 3rd course. Subsequently, fever and fatigue developed, and grade 3 liver damage was also noted, so he was admitted to Kindai University Hospital. A bone marrow aspirate examination was performed on the third day of illness, and a definitive diagnosis of hemophagocytic lymphohistiocytosis (HLH) was made. It was determined that immediate therapeutic intervention was necessary, and pulse therapy with methylprednisolone was started on the third day of illness. After 3 days of pulse treatment, a rapid recovery of platelet values, a decrease in ferritin levels, and a decrease in lactate dehydrogenase were observed. Subjective symptoms such as fever and fatigue also quickly improved.Conclusion: Early diagnosis and treatment for HLH resulted in a positive response. The number of HLH cases may increase in the future due to the expansion of immune checkpoint inhibitor indications.Keywords
This publication has 26 references indexed in Scilit:
- Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor MicroenvironmentCancer Research, 2018
- Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatmentRheumatology, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitorsAnnals of Oncology, 2017
- Macrophage activation syndrome: A new complication of checkpoint inhibitorsEuropean Journal of Cancer, 2017
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint InhibitorsJAMA Oncology, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Immune checkpoints in cancer clinical trialsChinese Journal of Cancer, 2014
- T-cell regulation by CD28 and CTLA-4Nature Reviews Immunology, 2001
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994